ClinicalTrials.gg
TerminatedNCT06041919Updated Jul 15, 2025Results posted

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

A Phase 2 interventional study of RESP301 and HRZE in Rifampicin Susceptible Pulmonary Tuberculosis, sponsored by Thirty Respiratory Limited. Terminated at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Thirty Respiratory Limited · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision was made by the sponsor not to progress to Stage 2

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing isoniazid in Tuberculosis, Pulmonary — 1 open to participants now, 2 under way, none of them phase 3. Isoniazid · Tuberculosis, Pulmonary.

Enrollment
14th of 14
20 · median 229
Started
2023
with 3 others
Phase 2
7 of 14
1 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Thirty Respiratory Limited

Among the 14 studies testing isoniazid in Tuberculosis, Pulmonary, this one is the 14th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 2, and was the 13th registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

1 of the 14 studies testing isoniazid in Tuberculosis, Pulmonary is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About isoniazid

Isoniazid: first FDA approval 1952 (NYDRAZID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing isoniazid in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

A Phase 2, Single-Centre, Open-Label, Parallel Control Arm, Randomised Clinical Study to Evaluate the Early Bactericidal Activity (EBA), Safety and Tolerability of Nebulised RESP301 in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

Read the detailed description

A total of approximately 15 participants will be recruited per treatment arm (total of approximately 75 participants in the study). Control arm participants will be split across sequential stages stages 1 and 2, with no stratification.

Stage 1: To determine the EBA of

  • Treatment Arm 1 (Active; n = 15) - inhaled RESP301 6 ml dosed via nebulisation administered three times daily over 14 days
  • Treatment Arm 2 (Control; n= 5) - HRZE taken orally once daily

On completion of Stage 1, recruitment will be paused and an interim analysis performed to determine whether the study should proceed to Stage 2.

Stage 2: To determine the EBA of

  • Treatment Arm 2 (Control; n= 10) - HRZE taken orally once daily
  • Treatment Arm 3 (Active; n = 15) - inhaled RESP301 6 ml dosed via nebulisation administered once daily over 14 days
  • Treatment Arm 4 (Active; n = 15) - inhaled RESP301 6 ml dosed via nebulisation administered twice daily over 14 days
  • Treatment Arm 5 (Active; n = 15) - inhaled RESP301 6 ml dosed via nebulisation administered three times daily in combination with HRZE taken orally once daily over 14 days
03

Conditions studied

  • Rifampicin Susceptible Pulmonary Tuberculosis

Keywords

  • Early Bactericidal Activity (EBA)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written, prior to all study-related procedures and agree to undergo all study procedures
  • Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
  • Newly diagnosed pulmonary TB
  • Rifampicin susceptible pulmonary TB as determined by molecular testing
  • Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 ml or more)
  • Spirometry performed during screening with a of ≥ 40%
  • Be of non- or willing to use effective methods of

Exclusion criteria

Exclusion Criteria:

  • positive AND CD4 \< 350 cells/mm3 OR are receiving antiviral therapy (ART)
  • Methaemoglobin saturation (SpMet) >3%
  • Female participant who is pregnant or breast-feeding
  • Participants planning to conceive a child within the anticipated period of study participation and for at least 90 days after the last dose of IMP in the study
  • Participation in other clinical studies with agents within 8 weeks prior to screening
  • Treatment received for this episode of TB with any drug active against M.tb
  • Treatment with medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic for more than 7 days within 2 weeks prior to screening.
  • Treatment with nitric oxide and other nitric oxide donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    1 (Active)

    Inhaled RESP301 6ml via nebulisation three times daily

    Drug: RESP301

  • Active comparator
    2 (Control)

    HRZE taken orally once daily

    Drug: HRZE

  • Experimental
    3 (Active)

    Inhaled RESP301 6 ml via nebulisation once daily

    Drug: RESP301

  • Experimental
    4 (Active)

    Inhaled RESP301 6 ml via nebulisation twice daily

    Drug: RESP301

  • Experimental
    5 (Active)

    Inhaled RESP301 6 ml via nebulisation three times daily plus HRZE taken orally once dialy

    Drug: RESP301 · Drug: HRZE

Interventions

06

What researchers measure

Primary outcomes

  1. Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Time to Positivity (TTP)

    Overnight sputum collection from which viable mycobacteria in the sample is quantified as TTP Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in TTP (hours) for treatment in each of the treatment groups

    Time frame: 0-2, 0-7, 0-14, 0-15 and 14-15 days

Secondary outcomes

  1. Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Colony Forming Units (CFU)

    Overnight sputum collection from which viable mycobacteria in the sample is quantified as CFU Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in CFU (Log10 CFU/mL) for treatment in each of the treatment groups

    Time frame: 0-2, 0-7, 0-14, 0-15 and 14-15 days

  2. Safety and Tolerability of Inhaled RESP301 Measured as Number of Treatment Emergent Adverse Events (TEAEs)

    Incidence of Treatment Emergent Adverse Events (TEAEs) will be presented by severity, drug relatedness, seriousness, leading to early withdrawal and leading to death.

    Time frame: Stage 1: Dosing period 14 days + Follow-up period 14 days. Stage 2: Participants did not enter the treatment phase due to early study termination

07

Results

Posted Jul 15, 2025

Participant flow

Participant flow — Overall Study
Milestone1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)
Started155000
Completed144000
Not completed11000
Withdrew: Lost to follow-up10000
Withdrew: At the request of the investigator or the sponsor01000

Outcome measures

PrimaryEarly Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Time to Positivity (TTP)

Overnight sputum collection from which viable mycobacteria in the sample is quantified as TTP Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in TTP (hours) for treatment in each of the treatment groups

Time frame:
0-2, 0-7, 0-14, 0-15 and 14-15 days
Reported as:
Median · Hours
Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Time to Positivity (TTP)
Hours1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)
0-23.5 (-5.2 to 5.6)63.5 (53.2 to 78.2)———
0-72 (-6.9 to 15)140.2 (117 to 160)———
0-142.5 (-7.8 to 9.1)167.8 (147.8 to 200.5)———
0-156.2 (-8 to 16.1)225 (157.8 to 247.5)———
14-157.5 (-3 to 17.5)2 (-5 to 47)———
SecondaryEarly Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Colony Forming Units (CFU)

Overnight sputum collection from which viable mycobacteria in the sample is quantified as CFU Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in CFU (Log10 CFU/mL) for treatment in each of the treatment groups

Time frame:
0-2, 0-7, 0-14, 0-15 and 14-15 days
Reported as:
Median · Log10 CFU/mL
Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Colony Forming Units (CFU)
Log10 CFU/mL1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)
0-20.3 (-0.1 to 0.5)-0.9 (-0.9 to -0.6)———
0-70.2 (-0.2 to 0.4)-1.2 (-1.6 to -0.8)———
0-140.4 (-0.2 to 0.8)-2.9 (-3.1 to -2.7)———
0-150.3 (-0.4 to 0.7)-2.4 (-3.6 to -1.4)———
14-150 (-0.3 to 0.1)0.1 (0.1 to 0.1)———
SecondarySafety and Tolerability of Inhaled RESP301 Measured as Number of Treatment Emergent Adverse Events (TEAEs)

Incidence of Treatment Emergent Adverse Events (TEAEs) will be presented by severity, drug relatedness, seriousness, leading to early withdrawal and leading to death.

Time frame:
Stage 1: Dosing period 14 days + Follow-up period 14 days. Stage 2: Participants did not enter the treatment phase due to early study termination
Reported as:
Number · events
Safety and Tolerability of Inhaled RESP301 Measured as Number of Treatment Emergent Adverse Events (TEAEs)
events1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)
Number of Grade 1 (Mild) TEAEs387———
Number of Grade 2 (Moderate) TEAEs132———
Number of Grade 3 (Severe) TEAEs20———
Number of Grade 4 (Life-threatening) TEAEs00———
Number of Unrelated TEAEs278———
Number of Related TEAEs261———

Adverse events

Collected over Stage 1: Dosing period 14 days + Follow-up period 14 days. Stage 2: Participants did not enter the treatment phase due to early study termination. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 (Active)0/15 (0%)0/15 (0%)15/15 (100%)
2 (Control)0/5 (0%)0/5 (0%)4/5 (80%)
3 (Active)———
4 (Active)———
5 (Active)———
Most frequent other events
Showing 10 of 28
Most frequent other events
Event1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)
CoughRespiratory, thoracic and mediastinal disorders13/150/5———
BronchospasmRespiratory, thoracic and mediastinal disorders6/150/5———
Abdominal PainGastrointestinal disorders2/151/5———
Vulvovaginal CandidiasisInfections and infestations1/151/5———
Otitis MediaInfections and infestations0/151/5———
Urinary Tract InfectionInfections and infestations0/151/5———
costcochondritisMusculoskeletal and connective tissue disorders0/151/5———
HeadacheNervous system disorders3/151/5———
Chest DiscomfortRespiratory, thoracic and mediastinal disorders0/151/5———
PruritusSkin and subcutaneous tissue disorders2/151/5———

Baseline characteristics

participants who received at least one dose of RESP301 or HRZE

Age, Continuous
Age, Continuous(years)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
Mean31.00 ± 10.0931.20 ± 5.93———31.05 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
Female21———3
Male134———17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
American Indian or Alaska Native00———0
Asian00———0
Native Hawaiian or Other Pacific Islander00———0
Black or African American155———20
White00———0
More than one race00———0
Unknown or Not Reported00———0
Weight
Weight(kg)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
Mean53.05 ± 9.8350.08 ± 6.76———52.31 ± 8.85
Height
Height(m)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
Mean1.69 ± 0.071.65 ± 0.05———1.68 ± 0.07
BMI
BMI(kg/m^2)1 (Active)2 (Control)3 (Active)4 (Active)5 (Active)Total
Mean18.70 ± 3.5818.34 ± 1.70———18.61 ± 3.17
08

Study locations

1 site
  • TASK Clinical Research Centre
    Cape Town, Bellville 7531, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD is confidential until the CSR is published

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Jul 2024, 9 months.

Results were first posted in Jul 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Sep 18, 2023
StartActual
Sep 27, 2023
Primary completionActual
Jul 24, 2024
CompletionActual
Mar 6, 2025
Results first posted
Jul 15, 2025
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06041919
Lead sponsor
Thirty Respiratory Limited
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Sep 27, 2023
Primary completion
Jul 24, 2024
Completion
Mar 6, 2025
Results posted
Jul 15, 2025
Last update
Jul 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RESP301 · Isoniazid · Rifampin · Pyrazinamide · Ethambutol

Start the discussion